Loading stock data…
Kamada Ltd. (KMDA)
$7.36+0.10 (+1.38%)
After Hours$7.36+0.00 (+0.00%)· Last close Jun 29
Kamada Ltd.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Kamada Ltd. in the Healthcare sector is trading at $7.36 with a market capitalization of $427M. Wall Street consensus targets $13.00 (4 analysts), implying a +76.6% move over the next 12 months. The stock is currently 21% below its 52-week high of $9.35, remaining 2.3% below its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +76.6% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $45.24M↑ | $44.68M↓ | $47.01M↑ | $44.75M↑ | $44.02M |
| Gross Profit | $19.12M↑ | $16.97M↓ | $19.76M↑ | $18.93M↓ | $20.75M |
| Operating Income | $6.95M↑ | $3.55M↓ | $7.82M↑ | $7.07M↓ | $7.79M |
| Net Income | $4.13M↑ | $3.56M↓ | $5.30M↓ | $7.38M↑ | $3.96M |
Peer Comparison
JNJUNHPFE
Fundamentals
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$427.26M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
21.11
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Strong income play. Yield provides a meaningful total return floor.
3.40%
ROE
Average efficiency. Growth may require heavy reinvestment.
7.85%
Volume
Today's trading volume
49,595
Recent News
Kamada Ltd (KMDA) Q1 2026 Earnings Call Highlights: Strategic Growth Amid Shipment Delays
Kamada Ltd (KMDA) reports steady revenue growth and strategic expansions despite temporary shipment challenges.
Kamada (KMDA) Q1 2026 Earnings Transcript
Importantly, this 2026 annual guidance is based currently solely on organic growth. As part of our commercial growth, we also anticipate growing our distribution segment through the launch of additional biosimilar products in the Israeli market as well as the expansion of the distribution business to the MENA region.
Kamada Ltd. Q1 2026 Earnings Call Summary
Moby summary of Kamada Ltd.'s Q1 2026 earnings call
Kamada Q1 Earnings Call Highlights
Kamada (NASDAQ:KMDA) reiterated its full-year 2026 outlook after reporting first-quarter results that management said were in line with expectations, excluding a temporary shipment delay that shifted revenue into April. Chief Executive Officer Amir London said demand across the company’s product po
Kamada (KMDA) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for Kamada (KMDA) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.